Israel Active

For the first time worldwide, researchers from Tel Aviv University and the Israel Institute for Biological Research have developed an mRNA-based vaccine that is 100% effective against plague bacteria, lethal to humans. It also works against antibiotic resistant bacteria.

Please read newsletter reader Lili Eylon’s personal account of Alpha DaRT radiation cancer therapy developed by Israel’s Alpha Tau (see previously). Lili was one of 56 patients in DaRT’s human study at Hadassah Medical Center – its second skin cancer human study in Israel.

61-year-old EMT Joelle Cohen retired from the medical field and joined United Hatzalah as a volunteer EMT. When a man in his 70s suffered a sudden cardiac arrest at a diabetes clinic in Jerusalem, Joelle revived him, saying it gave her one of the most incredible feelings.

20-year-old Kalim was sent home from hospital to die in St Petersburg after doctors said they could not treat his acute lymphoblastic leukemia. He immigrated to Israel where five months of CAR-T treatment at Rambam Health Care Campus gave Kalim back his life.

A nationwide study led by Jerusalem’s Hadassah hospital discovered that pregnant women brought into the Intensive Care Unit seriously ill with Covid-19, were more likely to improve if they gave birth (by Caesarian section) before their condition deteriorated. The data will save many lives.

The Nerivio device from Israeli startup Theranica (see previously) already has US FDA approval to treat acute migraines. It has now been approved for preventing migraines. Recent trials of 248 participants showed a huge improvement for those using Nerivio compared to those on a placebo device.

The US FDA has granted marketing authorization to the PMD-200 monitor developed by Israel’s Medasense Biometrics (see previously). The device monitors pain in non-communicating (e.g., anaesthetized) patients and already has made an impact in multiple countries.

Israel’s Protai has built a proteomics AI-based platform that comprehensively maps the course of a disease on the protein level. It can identify which patients will respond to a given treatment, as well as identifying identify diseases that a therapy should be able to treat.

Delray Medical Center is the first hospital in Florida to treat an Alzheimer’s disease patient using non-invasive focused ultrasound technology from Israel’s Insightec. The FDA-approved clinical trial will test reducing excessive protein buildup to open the blood-brain barrier.

Israel’s LDS Biotech has developed the Lyotropic treatment delivery system. Medications can be applied directly to the problem area without causing damage to organs such as the liver. It was successful in compassionate use and clinical (human) trials are being planned.